Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

CHMP recommends withdrawal of MA for Novartis’s Adakveo® (crizanlizumab)

May 26, 2023

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended that Adakveo® (crizanlizumab) should no longer be used to prevent painful crises in patients aged 16 years and older with sickle cell disease This follows a review by the CHMP, which concluded that the benefits of the medicine did not outweigh its risks The CHMP reviewed a clinical trial study which compared the effectiveness and safety of Adakveo® with placebo, and demonstrated that Adakveo® did not lead to a decrease in painful crises when compared to the placebo.